|
|
|
| Determination of the content and related substances of Methotrexate by HPLC method |
| Han Xiao |
| Hebei Jiheng Pharmaceutical Corporation Ltd., Hengshui 053400, China |
|
|
|
|
Abstract Methotrexate is a folic acid antagonist antitumor drug. A method for the determination of the content and related substances of methotrexate raw materials, providing a reference for the quality standard of methotrexate was established. The instrument was a Thermo Scientific UltiMate 3000 high-performance liquid chromatograph (HPLC), with a Thermo Scientific BDS HypersilTM C18 column (4.0 mm×250 mm, 5 μm); mobile phase: Mobile phase A: (20 mmol/L sodium dihydrogen phosphate, adjusted pH vaule to 6.0 with NaOH)∶ Acetonitrile=90∶10; Mobile phase B: (20 mmol/L sodium dihydrogen phosphate, adjusted pH vaule to 6.0 with NaOH)∶ Acetonitrile=50∶50; mobile phase A and mobile phase B were eluted according to the elution program; flow rate was 1.0 mL/min; detection wavelength was 280 nm; injection volume was 20 μL; column temperature was 30 ℃. The results showed that the concentration of methotrexate had a good linear relationship in the range of 0.50 ~ 1.50 mg/mL, with the linear equation y = 162.04x + 0.002 (r2 = 0.999); the detection limit was 1.813 μg/mL, and the quantification limit was 6.774 μg/mL; the solution stability indicated that the RSD within 12 hours was 0.25%; the repeatability RSD was 0.18% (n = 6); the intermediate precision RSD was 0.19% (n = 12); the average recovery rate of the added sample was 99.50% (RSD was 0.55%); the content of five batches of methotrexate raw materials was all within 98.0% ~ 102.0%. The results indicated that the method had strong specificity, good reproducibility and solution stability, and the intermediate precision and recovery rate met the requirements, and could be used to detect the content of methotrexate raw materials.
|
|
|
|
|
|
| [ 1 ] 陈兆鑫,宋文琪. 建立血清叶酸及代谢物和甲氨蝶呤血药浓度同时检测的方法[ J ]. 国际检验医学杂志,2024,45( 22 ):2 689 - 2 693,2 698.
[ 2 ] 李银英,周建华,焦红军. 甲氨蝶呤血药浓度监测分析[ J ]. 肿瘤基础与临床,2024,37( 1 ):70 - 71.
[ 3 ] 龚 妍,龚卫静,张玄龄,等. 药物暴露及多种基因多态性与儿童大剂量甲氨蝶呤药物不良反应的相关性研究[ J ]. 中国临床药理学杂志,2023,39( 15 ):2 145 - 2 149.
[ 4 ] Mohammadreza G, Duygu S S, Hamideh H, et al. Macromolecular design of pH sensitive, folic acid functionalized double hydrophilic block copolymer nanogels as methotrexate carriers to breast cancer cells[ J ]. Journal of Drug Delivery Science and Technology, 2023( 89 ): 1 129 - 1 134.
[ 5 ] 梁美卿. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的护理研究[ J ]. 智慧健康,2023,9( 24 ):231 - 234.
[ 6 ] 罗 珍,程天翠,王娅妮,等. 基于患者参与患者安全理论框架的干预在恶性淋巴瘤甲氨蝶呤化疗患者中的应用[ J ]. 护理学杂志,2021,36( 24 ):38 - 41.
[ 7 ] 周倩倩,易平勇,易嘉宁. 大剂量甲氨蝶呤不同给药持续时间治疗原发性中枢神经系统淋巴瘤的研究[ J ]. 肿瘤药学,2020,10( 4 ):467 - 471,496. |
|
|
|